AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16329018 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 10 micrograms/kg intravenously followed by meperidine 0.5 mg/kg intravenously (group 2)
Number of subjects: 44
Study 12387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 775
Study 12387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 5.0 mg
Number of subjects: 775
Study 12387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 775
Study 12387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 0.625 mg
Number of subjects: 775
Study 12387462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (all doses)
Number of subjects: 775
Study 12387462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study 10436259 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Acarbose
Number of subjects: 40
Study 10436259 — intervention group
Group type: COMPARATOR
Intervention: Insulin + Gliclazide
Number of subjects: 40
Study 7768667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral budesonide
Number of subjects: 0
Study 7768667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 0
Study 7768667 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) administration
Number of subjects: 0
Study 2179769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg per diem for 15 days)
Number of subjects: 12
Study 2179769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2179769 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 12
Study 2179769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 12
Study 2179769 — intervention group
Group type: COMPARATOR
Intervention: Heart attack patients
Number of subjects: 12
Study 380742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (5000 IU eight-hourly)
Number of subjects: 200
Study 31187264 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 4 L/min
Number of subjects: 18
Study 31187264 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 6 L/min
Number of subjects: 18
Study 31187264 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 8 L/min
Number of subjects: 18
Study 31187264 — intervention group
Group type: COMPARATOR
Intervention: High flow nasal cannula (4, 6, and 8 L/min)
Number of subjects: 18
Study 28956222 — intervention group
Group type: EXPERIMENTAL
Intervention: MindLight
Number of subjects: 174
Study 28956222 — intervention group
Group type: COMPARATOR
Intervention: Coping Cat (CBT)
Number of subjects: 174
Study 27805538 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC tool intervention group
Number of subjects: 357
Study 27805538 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 357
Study 25095314 — intervention group
Group type: EXPERIMENTAL
Intervention: McInnes bleaching
Number of subjects: 30
Study 25095314 — intervention group
Group type: COMPARATOR
Intervention: Enamel microabrasion
Number of subjects: 30
Study 25095314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study 22341702 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (C(0): 50 to 90 ng/ml)
Number of subjects: 34
Study 22341702 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) with low dose of cyclosporine (C(0): 100 to 150 ng/ml)
Number of subjects: 34
Study 22341702 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (in patients with baseline proteinuria)
Number of subjects: 34
Study 22341702 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (in patients without baseline proteinuria)
Number of subjects: 34
Study 21387802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) combined with pharmacotherapy
Number of subjects: 0
Study 21387802 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 21387802 — intervention group
Group type: COMPARATOR
Intervention: Standalone pharmacotherapy
Number of subjects: 0
Study 17557646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment for ankle plantarflexor spasticity, 15 treatment sessions, three days per week, every other day.
Number of subjects: 12
Study 17557646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham US) treatment for ankle plantarflexor spasticity, 15 treatment sessions, three days per week, every other day.
Number of subjects: 12
Study 15802964 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 3 Million Units three times per week for 24 or 48 weeks and ribavirin
Number of subjects: 22
Study 15802964 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha and ribavirin treatment
Number of subjects: 22
Study 12877822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg
Number of subjects: 23
Study 12877822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10419221 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally congruent intervention
Number of subjects: 0
Study 10419221 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 7486099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EP‐F)
Number of subjects: 30
Study 7486099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (EP‐L)
Number of subjects: 30
Study 7486099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (IV‐F)
Number of subjects: 30
Study 2270301 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin lock changed every 72 hours (Group A)
Number of subjects: 301
Study 2270301 — intervention group
Group type: COMPARATOR
Intervention: Heparin lock left in place up to 168 hours (Group B)
Number of subjects: 301
Study 7424031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 30
Study 7424031 — intervention group
Group type: COMPARATOR
Intervention: PR-D 92
Number of subjects: 30
Study 7424031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31488342 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupressure massage (TCAM)
Number of subjects: 20
Study 31488342 — intervention group
Group type: COMPARATOR
Intervention: Active recovery (AR)
Number of subjects: 20
Study 30922713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (twice-daily 20-min sessions for 5 days)
Number of subjects: 89
Study 30922713 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 89
Study 30027479 — intervention group
Group type: EXPERIMENTAL
Intervention: New mint-flavored nicotine gum (2 mg)
Number of subjects: 0
Study 30027479 — intervention group
Group type: EXPERIMENTAL
Intervention: New mint-flavored nicotine gum (4 mg)
Number of subjects: 0
Study 30027479 — intervention group
Group type: COMPARATOR
Intervention: Original flavor sugar-free nicotine gum (2 mg)
Number of subjects: 0
Study 30027479 — intervention group
Group type: COMPARATOR
Intervention: Original flavor sugar-free nicotine gum (4 mg)
Number of subjects: 0
Study 30027479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference gums
Number of subjects: 0
Study 27402599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7mg nicotine patch and placebo capsule)
Number of subjects: 82
Study 27402599 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (placebo patch and 40mg methylphenidate capsule)
Number of subjects: 82
Study 27402599 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo patch and capsule)
Number of subjects: 82
Study 25175269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol 3.0% ophthalmic solution, 1 drop, 6 times daily for 4 weeks before surgery
Number of subjects: 51
Study 25175269 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears, 6 times daily for 4 weeks before surgery
Number of subjects: 51
Study 22100822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously
Number of subjects: 52
Study 22100822 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 52
Study 19223653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meal
Number of subjects: 9
Study 19223653 — intervention group
Group type: COMPARATOR
Intervention: Low-GI meal
Number of subjects: 9
Study 17061043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear shape factor (highest quartile)
Number of subjects: 61
Study 17061043 — intervention group
Group type: COMPARATOR
Intervention: Nuclear size features and other shape factors
Number of subjects: 61
Study 15163089 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (24 mg/kg/day orally) for 1 month
Number of subjects: 47
Study 15163089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11597547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal enuresis group
Number of subjects: 106
Study 11597547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 10178338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary training programme
Number of subjects: 58
Study 10178338 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched professionals who did not attend training)
Number of subjects: 58
Study 7810147 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral diazepam
Number of subjects: 8
Study 7810147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2468266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder instillation chemotherapy of anticancer agents with OK‐432 intradermal injection (group A)
Number of subjects: 39
Study 2468266 — intervention group
Group type: COMPARATOR
Intervention: Intravesical instillation chemotherapy of anticancer agents (group B)
Number of subjects: 39
Study 31854069 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent cash incentives, peer mentors and usual care
Number of subjects: 144
Study 31854069 — intervention group
Group type: EXPERIMENTAL
Intervention: PEth ≥50 ng/mL
Number of subjects: 144
Study 31854069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous drinking reported on AUDIT
Number of subjects: 144
Study 31854069 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol use by PEth
Number of subjects: 144
Study 31854069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of alcohol use
Number of subjects: 144
Study 29304731 — intervention group
Group type: EXPERIMENTAL
Intervention: Volixibat (0.5 mg, 1 mg, 5 mg or 10 mg)
Number of subjects: 61
Study 29304731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27333481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic stretching technique
Number of subjects: 80
Study 27333481 — intervention group
Group type: COMPARATOR
Intervention: Sham-ultrasound procedure
Number of subjects: 80
Study 25081901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 103
Study 25081901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + Cetuximab
Number of subjects: 103
Study 23077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) for 30 min/day for 10 consecutive days
Number of subjects: 26
Study 23077933 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 26
Study 23077933 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (N=15)
Number of subjects: 26
Study 20620002 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic bandages
Number of subjects: 18
Study 20620002 — intervention group
Group type: COMPARATOR
Intervention: Elastic compression stockings
Number of subjects: 18
Study 18752510 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved tafluprost 0.0015% eyedrops
Number of subjects: 43
Study 18752510 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost 0.0015% eyedrops
Number of subjects: 43
Study 15883419 — intervention group
Group type: EXPERIMENTAL
Intervention: WELL diet (moderate-sodium, high-potassium, high-calcium, low-fat DASH diet)
Number of subjects: 63
Study 15883419 — intervention group
Group type: COMPARATOR
Intervention: LF diet (low-fat diet)
Number of subjects: 63
Study 12937909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 77
Study 12937909 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 77
Study 10678560 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate alone
Number of subjects: 371
Study 10678560 — intervention group
Group type: COMPARATOR
Intervention: Combined androgen blockade (long-term or short-term antiandrogen or short-term estrogen)
Number of subjects: 371
Study 9103022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cryotherapy
Number of subjects: 37
Study 8327677 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (one measurement in the morning and one in the evening)
Number of subjects: 10
Study 8327677 — intervention group
Group type: COMPARATOR
Intervention: Control group (two consecutive measurements in the morning)
Number of subjects: 10
Study 2951960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg at induction, incremental doses of 10 micrograms if necessary)
Number of subjects: 40
Study 2951960 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (3% prior to intubation, 0.9% during maintenance)
Number of subjects: 40
Study 2951960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 40
Study 2951960 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 2951960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 40
Study 2951960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil and Isoflurane
Number of subjects: 40
Study 29701037 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming acupuncture
Number of subjects: 64
Study 29701037 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study 29911849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract in NLC
Number of subjects: 120
Study 29911849 — intervention group
Group type: COMPARATOR
Intervention: 1% Diclofenac Gel
Number of subjects: 120
Study 26185393 — intervention group
Group type: EXPERIMENTAL
Intervention: JetPrep cleansing system
Number of subjects: 64
Study 26185393 — intervention group
Group type: COMPARATOR
Intervention: Standard bowel cleansing
Number of subjects: 64
Study 22995151 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace and foot orthotic
Number of subjects: 16
Study 22995151 — intervention group
Group type: COMPARATOR
Intervention: Knee brace
Number of subjects: 16
Study 22995151 — intervention group
Group type: COMPARATOR
Intervention: Foot orthotic
Number of subjects: 16
Study 22995151 — intervention group
Group type: COMPARATOR
Intervention: Control (no knee brace, no foot orthotic)
Number of subjects: 16
Study 22071279 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg per day pridopidine
Number of subjects: 437
Study 22071279 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg per day pridopidine
Number of subjects: 437
Study 22071279 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg per day pridopidine (per-protocol population)
Number of subjects: 437
Study 22071279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 19016257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy in schizophrenic women
Number of subjects: 73
Study 19016257 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy in schizophrenic men
Number of subjects: 73
Study 19016257 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 73
Study 16522907 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (3.4 g/d)
Number of subjects: 122
Study 16522907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 122
Study 12945880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct oral anticoagulation/anti‐platelet therapy (coumadin, dipyridamole, aspirin and heparin)
Number of subjects: 31
Study 12945880 — intervention group
Group type: COMPARATOR
Intervention: Adjunct anti‐platelet therapy with thienopyridin (ticlopidine, aspirin and heparin)
Number of subjects: 31
Study 11109978 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg implants
Number of subjects: 25
Study 11109978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estradiol 50 mg and testosterone 100 mg
Number of subjects: 25
Study 8924135 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms salbutamol
Number of subjects: 22
Study 8924135 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms salbutamol
Number of subjects: 22
Study 8924135 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study 1660011 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment, 1.5 x 10(6) IU subcutaneously three times for the first week followed by 3 x 10(6) IU three times weekly for a further 6 weeks.
Number of subjects: 120
Study 1660011 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, matching placebo injections.
Number of subjects: 120
Study 6175136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream 1% (50 micrograms)
Number of subjects: 37
Study 6175136 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream (Halog) 0.1% (50 micrograms)
Number of subjects: 37
Study 6175136 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguentum cetacei simplex (cold cream) (50 micrograms)
Number of subjects: 37
Study 6175136 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream base (rubbing)
Number of subjects: 37
Study 6175136 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 37
Study 31094842 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-TG distance measurement in PFI patients
Number of subjects: 48
Study 31094842 — intervention group
Group type: COMPARATOR
Intervention: TT-TG distance measurement in control patients
Number of subjects: 48
Study 31094842 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TT-TG distance between PFI and control groups
Number of subjects: 48
Study 31094842 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for TT-TG distance threshold
Number of subjects: 48
Study 31094842 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood ratios for TT-TG distance threshold
Number of subjects: 48
Study 31094842 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in correct PFI diagnosis using TT-TG distance
Number of subjects: 48
Study 28390807 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation (XNI) for 30 days
Number of subjects: 30
Study 28390807 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation (SNI) for 30 days
Number of subjects: 30
Study 26209543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 52
Study 26209543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26209543 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MMF vs Placebo
Number of subjects: 52
Study 23299002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 253
Study 23299002 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253
Study 23299002 — intervention group
Group type: EXPERIMENTAL
Intervention: Family connections and prosocial norms
Number of subjects: 253
Study 23299002 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer prosocial norms
Number of subjects: 253
Study 21989412 — intervention group
Group type: EXPERIMENTAL
Intervention: TERT572
Number of subjects: 48
Study 21989412 — intervention group
Group type: COMPARATOR
Intervention: TERT572Y
Number of subjects: 48
Study 19833274 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural analgesia (Group C)
Number of subjects: 40
Study 19833274 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (Group G)
Number of subjects: 40
Study 17074108 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily for 4 weeks
Number of subjects: 87
Study 15001263 — intervention group
Group type: EXPERIMENTAL
Intervention: RT preceded by chemotherapy (vincristine, etoposide, carboplatin, cyclophosphamide)
Number of subjects: 179
Study 15001263 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 179
Study 15001263 — intervention group
Group type: EXPERIMENTAL
Intervention: RT completed within 50 days
Number of subjects: 179
Study 15001263 — intervention group
Group type: COMPARATOR
Intervention: RT completed in more than 50 days
Number of subjects: 179
Study 15001263 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PF targeting deviation
Number of subjects: 179
Study 15001263 — intervention group
Group type: COMPARATOR
Intervention: Patients without PF targeting deviation
Number of subjects: 179
Study 11157465 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop squat exercises
Number of subjects: 19
Study 11157465 — intervention group
Group type: COMPARATOR
Intervention: Leg extension/leg curl exercises
Number of subjects: 19
Study 9216554 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/day)
Number of subjects: 14
Study 9216554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8091242 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy with drugs like 5-fluorouracil (5-FU), mitomycin, doxorubicin, and cisplatin
Number of subjects: 0
Study 8091242 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU-containing combinations
Number of subjects: 0
Study 8091242 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 0
Study 8091242 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agents (5-FU and mitomycin)
Number of subjects: 0
Study 8091242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-FU with radiation therapy
Number of subjects: 0